UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

July 20, 2021

Thomas G. Martin, MD, discusses the latest news in frontline, early relapsed, and heavily pretreated multiple myeloma, including the growing promise of quadruplets, emerging targets beyond BCMA, and the potential emergence of quadruplets, venetoclax, and antiviral therapy in amyloidosis.

June 28, 2021

Thomas G. Martin, MD, speaks to the FDA approval of isatuximab, carfilzomib, and dexamethasone, and potential future directors for isatuximab.

May 25, 2021

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

May 10, 2021

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

April 28, 2021

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

April 23, 2021

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

April 21, 2021

Nina Shah, MD, discusses the clinical significance of idecabtagene vicleucel for the treatment of patients with multiple myeloma.

April 07, 2021

Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.

April 05, 2021

Thomas G. Martin, MD, discusses the safety profile of bispecific T-cell engagers in multiple myeloma.

March 29, 2021

Mark Walters, MD, discusses the limitations of standard blood transfusions in pediatric patients with transfusion-dependent beta-thalassemia.

March 26, 2021

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

March 18, 2021

Thomas G. Martin, MD, discusses factors that can inform transplant eligibility in multiple myeloma.

March 15, 2021

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

March 09, 2021

Treatment strategies for patients with breast cancer, especially the combination of anthracyclines and HER2-targeted therapies, come with an increased risk of heart failure and cardiac toxicity.

March 08, 2021

Margetuximab represents an effective new therapeutic option that can be combined safely with a chemotherapy drug of choice for patients with metastatic HER2-positive breast cancer who have undergone multiple lines of prior treatment.

February 13, 2021

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

January 25, 2021

Hope S. Rugo, MD, FASCO, describes her work in medical oncology, previews the upcoming Miami Breast Cancer Conference, and speaks to what she is looking forward to in 2021 with regard to breast cancer treatment.

January 14, 2021

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

January 14, 2021

Young Hope Rugo saved up her S&H Green Stamps to buy a children’s chemistry set from a Sears catalog. At the age of 8, Rugo knew she wanted to be a scientist.

January 13, 2021